Mukesh Bharti — Lab Report Analysis & Clinical Context

🔬 Lab Results — Abnormal Findings Explained

Blood Count (CBC)

Liver Function Tests

Kidney Function Tests

• Dehydration / poor oral intake — very common in advanced cancer patients
• GI bleeding (less likely given other values)
• High protein catabolism from cancer

Platelets — Notably High

🦶 Right Foot Swelling — What Is Causing It?

1. Lymphedema — Metastatic lymph nodes in the pelvis or groin can block lymphatic drainage, causing unilateral leg/foot swelling. This is a well-recognized complication of pelvic/retroperitoneal lymph node metastases.
2. Deep Vein Thrombosis (DVT) ⚠️ — Pancreatic cancer is one of the most thrombogenic cancers known. It strongly activates coagulation (Trousseau's syndrome). Unilateral leg swelling in any cancer patient must be considered DVT until proven otherwise. This is a medical emergency requiring urgent Doppler ultrasound.
3. Hypoalbuminemia — Low albumin causes fluid to leak out of vessels. With albumin trending down, dependent edema can develop.

Action needed: An urgent Doppler ultrasound of the right leg should be done to rule out DVT.

🫁 Abdominal Heaviness/Swelling — What Is Causing It?

• Peritoneal seeding by cancer cells
• Lymphatic obstruction by lymph node metastases
• Low albumin reducing oncotic pressure

• Paracentesis (draining the fluid) can provide significant symptomatic relief when the abdomen is tense
• A permanent peritoneal drain (PleurX catheter) may be placed for repeated drainage at home
• Diuretics (spironolactone + furosemide) help in some cases, particularly if serum-ascites albumin gradient (SAAG) >1.1 g/dL
• Ultimately controlled only by controlling the underlying cancer

🧬 Overall Clinical Picture

⚕️ Urgent Recommendations for the Treating Doctor

1. Doppler ultrasound of the right leg — urgent, to rule out DVT (anticoagulation with LMWH such as enoxaparin is the treatment of choice for cancer-associated DVT)
2. Abdominal ultrasound or CT — to confirm and quantify ascites
3. Paracentesis — if ascites is confirmed and causing discomfort
4. Nutritional support — albumin trending down; high-calorie, high-protein supplementation or oncology dietitian referral
5. Oncology review — reassess chemotherapy regimen (FOLFIRINOX or gemcitabine/nab-paclitaxel are standard for metastatic disease, depending on performance status)
6. Palliative care team involvement — for pain management, nausea, quality of life optimization
7. Bone pain management — bisphosphonates (zoledronic acid) or denosumab for bone metastases to reduce skeletal-related events

⚠️ Important: This analysis is for clinical correlation by the treating physician only. It does not replace in-person medical assessment. The patient should be seen promptly given the symptom of unilateral limb swelling in the setting of active malignancy.

CECT Abdomen — Detailed Radiological Interpretation

🔍 Finding-by-Finding Analysis

1. Primary Tumor — Pancreatic Body Mass

• Hypodense with heterogeneous enhancement — the hallmark of pancreatic ductal adenocarcinoma on CECT (the dense desmoplastic stroma is hypovascular, so it enhances less than the surrounding pancreatic parenchyma)
• Size 3.5 cm → T2 stage by TNM 8th Edition (>2 cm but ≤4 cm = T2)
• Coeliac axis involvement → Upgrades to T4 — per TNM 8th Edition (AJCC/UICC), "Tumour involves the coeliac axis, superior mesenteric artery and/or common hepatic artery" classifies as T4, which is automatically unresectable and stage III–IV
• Retroperitoneal infiltration confirms locally advanced disease extending beyond the pancreatic capsule

From Grainger & Allison's Diagnostic Radiology: Tumour surrounding >180° of vessel circumference indicates vascular involvement. Coeliac axis encasement = T4, surgically unresectable.

2. Lymph Node Metastases

• Peripancreatic nodes = N1 disease (regional metastasis)
• Retroperitoneal (para-aortic) and retrocrural nodes = M1 disease (distant metastasis) — per Grainger & Allison's: "para-aortic lymph nodes are considered distant metastases, which preclude surgical resection"
• Necrosis within nodes (seen as central low density on CECT) confirms viable metastatic deposits — necrotic nodes are a sign of rapidly growing, high-burden nodal disease
• Retrocrural nodes (posterior to the diaphragmatic crura) = distant spread along the paraaortic chain

3. Omental Nodularity with Enhancement

• Omental caking/nodularity = peritoneal carcinomatosis — cancer cells have seeded the peritoneal surface
• This is the mechanism driving the severe ascites (see below)
• Confirms M1 disease (distant metastasis — peritoneal)
• Omental metastases from pancreatic cancer indicate very advanced, disseminated disease

4. Severe Ascites

• This is malignant ascites — caused by:
  • Peritoneal seeding (omental/peritoneal metastases disrupting lymphatic reabsorption)
  • Retroperitoneal lymphatic obstruction
  • Low albumin (hypoalbuminaemia reducing oncotic pressure — as seen in his labs)
• Harrison's Principles of Internal Medicine 22E states directly: "Patients with abdominal distention from ascites may report the new onset of an inguinal or umbilical hernia" — which exactly explains the next finding below

5. Left Inguinal Hernia Containing Ascites

• NOT a separate surgical problem requiring urgent repair in this context
• The hernia will not reduce until the ascites is controlled
• Risk: if the herniated bowel becomes trapped → incarceration/strangulation — a surgical emergency. The patient and family must be advised to report sudden pain, hardening, or redness at the hernia site immediately.
• Primary management is the ascites, not the hernia itself

6. Distal Pancreatic Atrophy + Mildly Dilated Main Pancreatic Duct (MPD)

• The tumor in the body is obstructing the main pancreatic duct upstream (toward the tail)
• This causes upstream duct dilatation and distal parenchymal atrophy (loss of acinar tissue from chronic obstruction)
• The normal pancreatic head confirms the lesion is confined to the body — NOT a head/periampullary cancer
• This also means no biliary obstruction (head is normal → bile duct not compressed → explains why his bilirubin was normal in the labs)
• Exocrine insufficiency (poor fat digestion, malabsorption) is likely from ductal obstruction and parenchymal loss → contributing to his malnutrition and falling albumin

📊 Final TNM Staging (AJCC 8th Edition)

🧩 Connecting the CT to His Symptoms

⚕️ Management Recommendations Based on CT Findings

Oncology

• Systemic palliative chemotherapy remains the primary treatment:
  • FOLFIRINOX (5-FU + leucovorin + irinotecan + oxaliplatin) — if ECOG performance status 0–1, adequate hepatic/renal function → median survival ~11 months
  • Gemcitabine + nab-paclitaxel — if older/frailer, performance status 1–2 → median survival ~8.5 months
  • Consider molecular profiling (BRCA1/2, KRAS G12C, NTRK, MSI-H) — targeted therapies available if actionable mutations found
• Bone metastases: Add zoledronic acid (bisphosphonate) or denosumab to reduce skeletal events and bone pain

Ascites Management

• Therapeutic paracentesis (drain 3–5 L at a time) for symptomatic relief of breathlessness, abdominal pain, and early satiety
• If recurrent: consider tunnelled peritoneal drain (PleurX catheter) for home drainage
• Diuretics (spironolactone 100–200 mg/day ± furosemide) may have limited benefit in malignant ascites but worth trialling

Inguinal Hernia

• No surgical repair at this time — the hernia is caused by ascites; repair will not hold
• Watch carefully for signs of incarceration: sudden severe pain, irreducibility, erythema
• Control ascites → hernia will reduce

Nutrition

• Pancreatic enzyme replacement therapy (PERT) — e.g., Creon (pancrelipase) with every meal — essential given pancreatic duct obstruction and exocrine insufficiency
• High-calorie, protein-rich diet; oncology dietitian referral
• Monitor albumin regularly

Palliative Care

• Early specialist palliative care team involvement for pain (coeliac axis plexus involvement → severe epigastric/back pain), nausea, fatigue, psychological support
• Coeliac plexus neurolysis (via EUS or CT-guided) — highly effective for pain control in pancreatic body tumours involving the coeliac axis

Summary

• Coeliac axis encasement → unresectable T4
• Multi-station nodal disease including para-aortic and retrocrural nodes → M1
• Omental metastases → peritoneal carcinomatosis → M1
• Severe malignant ascites → driving the abdominal swelling and the inguinal hernia
• Distal pancreatic atrophy from ductal obstruction

⚠️ All findings and recommendations are for the treating oncologist's clinical correlation. This report does not replace specialist multidisciplinary team assessment.

Evaluation of Dr. Vineet Govinda Gupta's Treatment Plan

What the Notes Tell Us (Decoded)

• 6 cycles FOLFIRINOX → Mixed response + mild progression (Jan 2026)
• 4 cycles Gemcitabine/Nab-paclitaxel + 1 dose Pembrolizumab (21/5/26) → Clinical progression with malignant ascites
• Two standard chemotherapy lines have now failed
• Current ECOG PS: 1 (good functional status)

The Proposed Treatment Plan — Assessment

✅ 1st Choice: "Inefa MUC1 → ADC Trial (Dr. Sameer Rastogi, AIIMS)"

• "Inefa MUC1" likely refers to an anti-MUC1 Antibody-Drug Conjugate (ADC) clinical trial
• MUC1 (Mucin-1) is overexpressed in ~90% of pancreatic cancers, making it an attractive target
• Dr. Sameer Rastogi is a Medical Oncologist at AIIMS New Delhi with active involvement in gastrointestinal and novel cancer trials
• ADCs deliver cytotoxic drugs directly to cancer cells via a targeted antibody — this class of drugs has produced major breakthroughs (e.g., in breast cancer)
• Why this is smart: After 2 failed standard chemotherapy lines, a clinical trial with a novel agent is the most evidence-aligned recommendation. This is exactly what international guidelines (NCCN, ESMO) recommend at this stage.
• Verdict: ✅ Excellent first choice. Access to a clinical trial at a top institution like AIIMS is the best option available.

✅/⚠️ 2nd Choice: Pembrolizumab + Lenvatinib OR Pembrolizumab + Rucaparib

• Tested in the LEAP-005 Phase II trial (published 2026)
• In the PDAC cohort: ORR only 7.8%, with grade 3-4 toxicity in 59.2% of patients
• Lenvatinib is a VEGF/VEGFR inhibitor; the combination tries to create an immunogenic tumour environment
• Verdict: ⚠️ Scientifically rational but modest activity. PDL1 50% makes immunotherapy a logical choice, but the response rate is low. It may be appropriate if no trial is available.

• Rucaparib is a PARP inhibitor (RUCAPANC2 trial showed OS of 23.5 months — but in BRCA/PALB2 mutated patients on maintenance after platinum response)
• This patient's genomic profile shows PBRM1 loss and MAP2K1 loss — but no clear BRCA1/2 or PALB2 mutation is documented, which is the key biomarker for PARP inhibitor benefit
• The POLAR trial (ESMO 2024) showed pembrolizumab + olaparib benefited patients with HRD/BRCA mutations
• Verdict: ⚠️ Theoretically interesting given PBRM1 loss (chromatin remodelling dysfunction may contribute to HRD), but without confirmed BRCA/PALB2 mutation, the evidence is weak. Would need HRD testing to confirm eligibility. Not unreasonable to try if PDL1 50% is used as rationale alongside PBRM1 loss.

✅ 3rd Choice: Liposomal Irinotecan (Onivyde) + S1/5-FU

• Liposomal irinotecan (nal-IRI/Onivyde) + 5-FU/LV is FDA-approved for metastatic PDAC after gemcitabine-based therapy (NAPOLI-1 trial)
• Multiple real-world studies (2024-2025) confirm its benefit even in borderline performance status patients
• The 2025 multi-centre study showed long-term survival achievable in select patients
• After failure of both FOLFIRINOX and Gem/Nab-Pac, liposomal irinotecan + 5-FU is the most evidence-supported standard third-line option
• Verdict: ✅ Strongly appropriate. This arguably should be the 2nd choice (before experimental combinations), but placing it 3rd to prioritise a trial is reasonable.

⚠️ 4th Choice: "Eeledinib" (likely Erlotinib or a novel agent)

• If this is erlotinib (EGFR inhibitor): It has very limited activity in PDAC and is not a standard recommendation at this stage. It is not recommended by NCCN guidelines for post-second-line PDAC.
• If this refers to a newer oral agent (possibly a MEK/ERK inhibitor given MAP2K1 loss): this could be rational but is investigational.
• Verdict: ⚠️ Unclear. The handwriting is difficult to read. If erlotinib, it is a weak choice at this stage. The doctor should clarify what specific agent this refers to.

The ALP Drop (165 → 117 after 1st Keytruda)

• The ALP drop is encouraging but did not reflect overall disease control
• It may reflect bone remodelling changes rather than true response
• The decision to change the regimen despite this one positive signal is correct — overall disease was progressing

Overall Verdict: Is the Doctor's Plan Good?

⚠️ This assessment is for informational purposes only and does not replace the treating oncologist's judgment. All treatment decisions must be made by the patient's medical team with full clinical context.

Best Line of Approach — My Assessment

The Single Most Important Finding Right Now

Why Daraxonrasib Should Be the Priority

• FDA issued "safe to proceed" letter on May 1, 2026 for Expanded Access Protocol (EAP)
• Available to previously treated metastatic PDAC patients with no comparable alternative who cannot join a clinical trial
• Physician must apply directly to Revolution Medicines (media@revmed.com / revmed.com)
• EAP is currently US-based — access from India requires either:
  1. Travel to the US for treatment, or
  2. Contact with Revolution Medicines directly to explore compassionate use / international access

My Recommended Priority Sequence

Step 1 — IMMEDIATE: Apply for Daraxonrasib Expanded Access

• Dr. Gupta or the treating oncologist contacts Revolution Medicines directly at revmed.com and requests EAP access for this patient
• The patient has: metastatic PDAC, KRAS G12V confirmed on NGS, 2 prior lines failed, no satisfactory alternative
• He meets the eligibility criteria on paper
• Given the patient is in India, this may require legal/regulatory navigation — an oncology centre with international connections (AIIMS, Tata Memorial) would be the best route to facilitate access
• This should happen in parallel with all other decisions, not sequentially

Step 2 — Immediately Alongside: AIIMS Clinical Trial (Dr. Sameer Rastogi)

• MUC1 is overexpressed in ~90% of PDAC
• ADC (Antibody-Drug Conjugate) technology delivers chemotherapy directly to cancer cells
• If the patient cannot access daraxonrasib, a trial at AIIMS is the next best step
• Both paths (daraxonrasib access + AIIMS trial enquiry) should be pursued simultaneously — whichever opens first, the patient takes

Step 3 — Symptom Control and Performance Status Maintenance (MUST run in parallel with Steps 1–2)

Step 4 — If Daraxonrasib/Trial Access Fails: Liposomal Irinotecan + 5-FU/LV (Onivyde regimen)

• NAPOLI-1 trial: FDA-approved for PDAC after gemcitabine-based therapy
• The patient has received both FOLFIRINOX (irinotecan-containing) and Gem/Nab-Pac
• Important caveat: patient received irinotecan in FOLFIRINOX — there may be partial cross-resistance, but liposomal encapsulation delivers higher irinotecan concentrations to tumour cells than standard irinotecan, so it can still be effective
• Bilirubin is currently normal (0.47 mg/dL) — this regimen cannot be given if bilirubin rises above normal limit
• Dose: Liposomal irinotecan 70 mg/m² IV + 5-FU 2400 mg/m² + leucovorin 400 mg/m² every 2 weeks

Step 5 — Pembrolizumab + Lenvatinib (Dr. Gupta's 2nd choice)

• LEAP-005 trial ORR in PDAC was 7.8% — modest but real
• Grade 3-4 toxicity in 59% — significant burden, especially with ascites and borderline albumin
• Best reserved for patients with better nutritional status and controlled ascites

What I Would NOT Do Right Now

• Do not give another cycle of pembrolizumab alone — the disease progressed on Gem/Nab-Pac + pembrolizumab (MMR-proficient tumour; single agent anti-PD1 has no proven role in MMR-proficient PDAC)
• Do not rush to erlotinib (4th choice) — minimal activity in PDAC; no molecular rationale in this profile
• Do not attempt surgery or local ablation — coeliac axis invasion + peritoneal mets + ascites makes any surgical intervention extremely high risk with no survival benefit
• Do not delay symptom management waiting for a trial decision — the two tracks must run in parallel

Summary Recommendation

IMMEDIATE (THIS WEEK):
├── 1. Apply for daraxonrasib EAP via physician → Revolution Medicines
├── 2. Refer to Dr. Sameer Rastogi, AIIMS for MUC1-ADC trial
└── 3. Therapeutic paracentesis + Doppler leg ultrasound

ONGOING PARALLEL:
├── PERT, nutrition, bone protection (zoledronic acid), pain control
└── Monitor ALP, albumin, bilirubin weekly

IF TRIAL ACCESS DELAYED/DENIED (2-4 WEEKS):
└── Liposomal irinotecan + 5-FU/LV (NAPOLI-1 regimen)

ECOG PS must be preserved at 1 — this is the gateway to all other options

⚠️ This represents an informed clinical analysis for discussion with the treating oncology team. All treatment decisions must be made by the patient's physicians with full consent and clinical context.